Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Defense was posted on August 20, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Notice of Intent to Sole Source - Automated Refraction System

Awarded
HT001426QE034Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The Defense Health Agency has issued a notice of intent to sole source the procurement of three Marco EPIC 6100 Refraction Systems and three Marco TRS-6100 Automated Refraction Systems for use at Fort Campbell, Kentucky. These specific Nidek Global products are being sought through Marco Lombart, the exclusive authorized distributor for North America, to ensure complete compatibility and integration with the facility's existing Marco Lombart autorefractors. This requirement is driven by the need to maintain a seamless ophthalmic examination workflow and prevent the creation of data silos within the current clinical environment. This solicitation, identified by number HT001426QE034, is categorized as a Small Business Set Aside. The procurement process is managed by the Department of Defense and is subject to a response deadline of August 26, 2026. Interested parties or those wishing to challenge the sole source designation should contact the designated points of contact, Jessie Hart or Lorena Cruz, regarding this requirement under NAICS code 339112.

General Info

DHA sole source procurement of Marco refraction systems for Fort Campbell, Kentucky.

NAICS

339112 - Surgical and Medical Instrument Manufacturing

Place of Performance

Fort Campbell, KY, USA

Set-Aside

SBA

Documents

1

FY260905 Sole Source Justification - Marco Lombart Refraction System

PDF, High priority: read this first5 pages · justification-and-authorization
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseAwarded
Posted

special-notice

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency (dha)
Contacts2 people available
OfficeN/A
Office AddressN/A
Contacts

Full Description

Show more

This is a notice of intent to sole source three (3) Marco EPIC 6100 Refraction Systems and three (3) Marco TRS-6100 Automated Refraction Systems. These products are manufactured by Nidek Global, with Marco Lombart serving as their exclusive authorized distributor for North America. The equipment must be exactly compatible and fully integrate with the existing Marco Lombart autorefractors currently in use at the facility to ensure a seamless ophthalmic examination workflow and prevent data silos.

More opportunities from Department Of Defense → Defense Health Agency (dha)

Same awarding agency

NAICS: 325412
Federal
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Solicitation # HT9402-26-Q-9404
The Defense Health Agency, acting for the Department of War, is soliciting quotes under solicitation HT9402-26-Q-9404 to establish Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program agreements. This procurement is mandated by 10 U.S.C. 1074g to create an integrated pharmacy benefits program for the Military Health System, covering Military Treatment Facilities, the TRICARE Mail Order Pharmacy, and the Basic Core Formulary. The Pharmacy and Therapeutics Committee will evaluate pharmaceutical agents based on relative clinical effectiveness and cost effectiveness to determine their placement on the Uniform Formulary. Specifically, the November 2026 review includes twelve newly approved drugs across various classes, including oncological agents, antifungals, and insulins. Interested manufacturers must submit quotes by October 26, 2026, and provide detailed clinical data regarding the advantages and therapeutic placement of their drugs. Key requirements include maintaining active SAM.gov registration, ensuring Trade Agreements Act compliance via FAR 52.225-6, and agreeing to utilize the Department of War Prime Vendor Program for distribution. The agreement also requires opening limited distribution channels to Accred for mail order services. Award decisions are based on the combined evaluation of clinical and cost effectiveness, with the TRICARE retail network utilization accrual beginning upon the Contracting Officer's signature. The contract allows for termination by either party with 120 days written notice.
Pharmaceutical Preparation Manufacturing

POSTED

13 days ago

DEADLINE

in 6 days
View Details
NAICS: 541715
Federal
DHA Enterprise-Wide Commercial Solutions Opening (CSO)
Solicitation # HT003826SC005
The Defense Health Agency (DHA) has established the Enterprise-Wide Commercial Solutions Opening (CSO), solicitation number HT003826SC005, to identify and acquire commercial products, services, and non-developmental items. Active from August 7, 2026, through August 6, 2027, this initiative seeks commercially available capabilities that can be deployed immediately or modified to meet DHA requirements across its Medical Digital Solutions, Medical Services, and Medical Products portfolios. The government will utilize a variety of award vehicles, including firm-fixed-price FAR-based contracts and Other Transaction (OT) agreements for research, prototyping, and experimental purposes under authorities such as 10 U.S.C. 3458, 3201, 4021, 4022, and 4023. The procurement process is driven by the issuance of specific Areas of Interest (AoI), which define problem statements, objectives, and submission criteria. Submissions undergo a streamlined, multi-phase evaluation process: Phase I involves a pitch or white paper evaluated on a Go/No-Go basis for strategic alignment and feasibility; Phase II may include an optional oral presentation or demonstration to assess technical viability; and Phase III requires a full commercial proposal evaluated on technical merit, cost reasonableness, and past performance. This CSO is administered by the DHACA Defense Healthcare Management Systems Contracting Division and is designed to prioritize cost-effective, commercially viable solutions to enhance healthcare readiness and patient safety.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

21 days ago

DEADLINE

N/A
View Details
NAICS: 561910
Federal
DHA - Offsite Sterile Processing Support Services
Solicitation # HT9427-27-RFI-0001
The Defense Health Agency (DHA) is issuing a Request for Information (RFI) to identify qualified contractors capable of providing offsite Sterile Processing (SP) support for various Military Treatment Facilities (MTFs) across eight DHA networks. This initiative is part of a Business Case Analysis to improve service resilience and workload stability, ensuring that surgical capabilities are not halted by onsite equipment failures. The scope of work involves the transportation of surgical instruments between MTFs and contractor-owned offsite facilities, where the contractor will provide the necessary personnel, equipment, and facilities to perform decontamination, assembly, sterilization, inventory verification, and quality control. The equipment to be processed includes specialized items such as minimally invasive surgical cases, Da Vinci accessories, and power equipment, with an estimated volume of approximately 2,000 trays monthly per participating MTF. This RFI is strictly for market research and planning purposes and does not constitute a formal solicitation or an obligation to award a contract. The DHA is seeking capability statements from healthcare companies and hospitals that detail their experience with similar projects over the last five years and their proposed implementation strategy. Responses must be submitted in PDF format to the designated Contract Specialist by 11:00 AM EDT on October 30, 2026, and are limited to 10 pages using a 12-point font. The government has not yet determined if a small business set-aside is appropriate and will use the information gathered from these responses to make that decision.
Packaging and Labeling Services

POSTED

22 days ago

DEADLINE

in 10 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS